Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.18 | -0.22 | -0.46 |
| FCF Yield | -16.97% | -20.09% | -30.77% | -9.07% |
| EV / EBITDA | -5.94 | -4.38 | -2.33 | -8.90 |
| Quality | ||||
| ROIC | -48.20% | -66.65% | -95.14% | -49.08% |
| Gross Margin | 24.43% | -804.54% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 0.81 | 0.74 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 5.22% | -22.65% | -17.95% | -5.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.09 | 0.39 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | -133.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.41 | 1.04 | 0.00 | 0.00 |
| Cash Conversion Cycle | 224.94 | -725.76 | -459.43 | -714.78 |